March 3, 2008 - Neurobiological Technologies, Inc. (Nasdaq: NTII) and the Buck Institute for Age Research (Buck) announced today they have entered into a collaboration and exclusive license agreement to develop a novel therapy for Alzheimer's Disease (AD). Under the terms of the agreement Neurobiological Technologies will exclusively license certain patent rights related to a naturally occurring protein that has been shown in animals to reverse the symptoms of Alzheimer's disease.AD is a neurodegenerative disease that, in its most common form, occurs in people over 65 years old and is the most common cause of dementia afflicting 24 million people worldwide.
AD Research at the Buck Institute focuses on signal transduction pathways that may explain all of the different, yet seemingly opposed theories of AD, namely that AD is caused by either an overabundance of amyloid-B (AB) peptide, or neurofibrillary tangles that build up inside the nerve cells. Current studies at the Buck are focused on a naturally occurring protein that has been shown in both cell culture and mice to inhibit the production of amyloid-B (AB) peptides while simultaneously facilitating the growth and preservation of nerve fibers in the brain... Neurobiological Technologies' Press Release -
Blog Archive
-
▼
2008
(79)
-
▼
March
(11)
- ExonHit, EHT 0202 Counters Scopolamine's Detriment...
- Cryo-Cell International : Umbilical Cord Blood Cel...
- Evotec's EVT 101 : to Penetrate the Brain in Man a...
- Eisai, Application for Aricept Oral Jelly Formulat...
- Neurobiological Technologies and Buck Institute, t...
- Bar Harbor BioTechnology : New Line of StellARrays
- Power3 Medical , Three Hundred Patient Clinical Va...
- Pharmatrophix Alzheimer's Drug Discovery Foundatio...
- Hunter-Fleming and Newron, continuation of phase I...
- Debiopharm's Debio 9902 SR in Alzheimer’s disease,...
- Power3 Medical, Patent Application for Forty-Seven...
-
▼
March
(11)